Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...

Novo Nordisk, the company behind blockbuster weight-loss drugs like Ozempic and Wegovy, had a deal with Hims & Hers that ...

However, the relationship soured quickly as Novo Nordisk discovered that “Hims & Hers Health, Inc. has failed to adhere to ...

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...

Hims & Hers (HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk (NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on ...